Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.55 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.52 |
| ▸ | RAF1 | P04049 | 3/20 | 0.52 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | STK4 | Q13043 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15319791 | 1.00 | EGFR (0.61) | EGFRERBB2MAP2K1RAF1MAPK3 | |
| SCHEMBL15319835 | 0.88 | EGFR (0.67) | EGFRERBB2 | |
| SCHEMBL15319830 | 0.88 | EGFR (0.67) | EGFRERBB2 | |
| SCHEMBL15319833 | 0.88 | EGFR (0.67) | EGFRERBB2 | |
| SCHEMBL15319836 | 0.88 | EGFR (0.67) | EGFRERBB2 | |
| SCHEMBL15320707 | 0.86 | EGFR (0.72) | EGFRERBB2MAP2K1RAF1STK4 | |
| SCHEMBL28804928 | 0.85 | EGFR (0.63) | EGFRERBB2 | |
| SCHEMBL15391596 | 0.84 | EGFR (0.78) | EGFRERBB2 | |
| SCHEMBL15391598 | 0.84 | EGFR (0.78) | EGFRERBB2 | |
| SCHEMBL15320702 | 0.83 | EGFR (0.71) | EGFRERBB2MAP2K1RAF1STK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353062-B2 | Substituted quinolines as bruton's tyrosine kinases inhibitors | HANGZHOUDERENYUCHENG BIOTECHNOLOGY LTD (CN) | 2016-05-31 | — | — | US | claimed |
| US-20150057312-A1 | SUBSTITUTED QUINOLINES AS BRUTON'S TYROSINE KINASES INHIBITORS | HANGZHOUDERENYUCHENG BIOTECHNOLOGY LTD (CN) | 2015-02-26 | — | — | US | claimed |
| EP-2833886-A1 | SUBSTITUTED QUINOLINES AS BRUTON'S TYROSINE KINASES INHIBITORS | HangzhouDeRenYuCheng Biotechnology Ltd. (CN) | 2015-02-11 | — | — | EP | claimed |
| WO-2013152135-A1 | SUBSTITUTED QUINOLINES AS BRUTON'S TYROSINE KINASES INHIBITORS | ZHANG DAWEI (US) | 2013-10-10 | — | — | WO | claimed |
| US-9353062-B2 | Substituted quinolines as bruton's tyrosine kinases inhibitors | HANGZHOUDERENYUCHENG BIOTECHNOLOGY LTD (CN) | 2016-05-31 | — | — | US | disclosed |
| US-20150057312-A1 | SUBSTITUTED QUINOLINES AS BRUTON'S TYROSINE KINASES INHIBITORS | HANGZHOUDERENYUCHENG BIOTECHNOLOGY LTD (CN) | 2015-02-26 | — | — | US | disclosed |
| EP-2833886-A1 | SUBSTITUTED QUINOLINES AS BRUTON'S TYROSINE KINASES INHIBITORS | HangzhouDeRenYuCheng Biotechnology Ltd. (CN) | 2015-02-11 | — | — | EP | disclosed |
| WO-2013152135-A1 | SUBSTITUTED QUINOLINES AS BRUTON'S TYROSINE KINASES INHIBITORS | ZHANG DAWEI (US) | 2013-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057312-A1 | SUBSTITUTED QUINOLINES AS BRUTON'S TYROSINE KINASES INHIBITORS | BTK, ABL1, LYN | EGFR 1627/4885ERBB2 206/4885MAP2K1 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.